FDA and the University College of Medical Sciences, University of Delhi cosponored a Feb. 18-20 conference on generic drugs, bioequivalence amd pharmacokinetics, held in New Delhi, India. The U.S. contingent included: FDAers: Marvin Seife, MD, Director Division of Generic Drugs; Shrikant Dighe, PhD, Director Division of Bioequivalence, Ramakat Mhatre, PhD, Bioequivalence Branch III Chief; Vinod Shah, PhD, Science, Management Operations and Policy Branch Chief; Walter Batts, Deputy Director of International Affairs Staff; and Dr. John Wagner, University of Michigan; Dr. James Doluisio, University of Texas; and Milton Kaplan, Parke-Davis.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.